Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

Home

JANX

J

Janux Therapeutics, Inc. (JANX)

NGM – Цена в реальном времени. Валюта: USD

13.18

-0.45 (-3.30%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

13.18

0.00 (0.00%)

После закрытия: Mar 27, 2026, 7:55 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update. “The past year marked a period of significant execution and progress for Janux as we continued to translate the promise of our tumor-activated platform into meaningful clinical and strategic advance.

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011.

Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year

Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year

Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%.

Wall Street Analysts See a 319.23% Upside in Janux Therapeutics (JANX): Can the Stock Really Move This High?

Wall Street Analysts See a 319.23% Upside in Janux Therapeutics (JANX): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 319.2% in Janux Therapeutics (JANX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer

Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced that William Go, M.D., Ph.D., has been appointed Chief Medical Officer, effective January 26, 2026. Dr. Go succeeds Zachariah McIver, D.O., Ph.D., who will be leaving th.

JANX Enters Global Oncology Collaboration With BMY, Stock Rises

JANX Enters Global Oncology Collaboration With BMY, Stock Rises

Janux Therapeutics struck a global licensing deal for its tumor-activated platforms, sending shares higher and expanding its reach in solid tumors.

Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million

Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million

Janux Therapeutics, Inc. (NASDAQ: JANX) on Thursday announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb Co. (NYSE: BMY).

Видео

No Data

There is no data to display

Пресс-релизы

Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update. “The past year marked a period of significant execution and progress for Janux as we continued to translate the promise of our tumor-activated platform into meaningful clinical and strategic advance.

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011.

Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer

Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced that William Go, M.D., Ph.D., has been appointed Chief Medical Officer, effective January 26, 2026. Dr. Go succeeds Zachariah McIver, D.O., Ph.D., who will be leaving th.

Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors

Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (“Janux”), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb. Under the terms of the agreement, th.